Syndax Pharmaceuticals is a late-stage clinical development oncology company focused on overcoming the problem of resistance in cancer therapy. Syndax is currently focused on developing an innovative pipeline of combination therapies in multiple cancer indications. The Company's lead product candidate, entinostat, is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor-positive breast cancer, and as a combination therapeutic in Phase 1b/2 clinical trials for ovarian cancer. Concurrently, Syndax is also developing SNDX-6352, an IND-ready anti-CSF-1R monoclonal antibody, to potentially enhance the body’s immune response on tumors that have shown sensitivity to immunotherapy.